Lanean...
Safety of switching between rituximab biosimilars in onco-hematology
Comparable clinical efficacy and safety of the reference rituximab (MABTHERA) and its biosimilars has been established in randomized trials. However, safety concerns are often raised when switching from reference to biosimilar products and between different biosimilars. In this prospective observati...
Gorde:
| Argitaratua izan da: | Sci Rep |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Nature Publishing Group UK
2021
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7966361/ https://ncbi.nlm.nih.gov/pubmed/33727667 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-85563-1 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|